Chimeric antigen receptors (CAR) are engineered fusion proteins designed to target T cells
to antigens expressed on cancer cells. CAR T cells are now an established treatment for …

Radiation-induced second malignancies (RISM) is one of the important late side effects of
radiation therapy and has an impact on optimal treatment decision-making. Many factors …

We report a T cell lymphoma (TCL) occurring 3 months after anti-CD19 chimeric antigen
receptor (CAR) T cell immunotherapy for non-Hodgkin B cell lymphoma. The TCL was …

Background In this review, we examine the continually expanding and increasingly
compelling data linking radiation and various chemicals in our environment to the current …

PURPOSE Anti-CD19 chimeric antigen receptors (CARs) are artificial fusion proteins that
cause CD19-specific T-cell activation. Durability of remissions and incidence of long-term …

Adoptive T cell therapies have produced exceptional responses in a subset of patients with
cancer. However, therapeutic efficacy can be hindered by poor T cell persistence and …

Second malignant neoplasms (SMNs) and cardiovascular disease (CVD) are among the
most serious and life-threatening late adverse effects experienced by the growing number of …

Purpose Previous studies have shown increased risks of second malignancies after non-
Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL); however, no earlier …

The time trend of mesothelioma incidence and projections of future cases provide useful
information for analyzing proposed public health interventions where asbestos exposure …

Introduction As chimeric antigen receptor T-cell therapies are becoming increasingly
available in the armamentarium of the hematologist, there is an emerging need to monitor …